Tianjin Pharmaceutical Da Ren Tang (SGX:T14) estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.
The increase will represent a 180% to 204% year over year.
The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH SARL for around 1.54 billion yuan.
Shares of the company were up nearly 1% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。